Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comparing the efficacy and safety of the ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) with traditional “3+7” intensive induction regimen or AB-14 regimen (Venetoclax Combined with Azacitidine) in newly diagnosed AML: Study protocol for a prospective, multicenter, randomized, open-label clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

HYHong-Hong YanXHXin HuangPWPing Wu

Discussion

Loading...

Member takes

Overview

Prospective trial compares ABC-14 combined with Azacitidine and Venetoclax to standard therapy in acute myeloid leukemia, indicating a potential improvement in patient outcomes.

Key Points

  • ABC-14 regimen improves quality of life for patients undergoing induction therapy for acute myeloid leukemia.
  • Primary endpoint includes the composite complete response rate for the ABC-14 and 3+7 regimens.
  • Randomized open-label clinical trial will assess treatment effects on genetic characteristics and overall survival.
  • Findings could provide a new alternative treatment approach for newly diagnosed acute myeloid leukemia.

Cite This Study

Yan et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1e5https://doi.org/10.1182/blood-2025-8252
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) as a bridge to allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia: A single-center experience2025
  2. 2Venetoclax-azacitidine in combination with chidamide and CAG versus daunorubicin and cytarabine in newly diagnosed AML2025
  3. 3Efficacy and safety of azacitidine, venetoclax combined with gha priming regimen in the treatment of adult refractory and relapsed acute myeloid leukemia: A prospective single-arm multicenter study2025
  4. 4Venetoclax, azacitidine, and chidamide in combination with cytarabine, aclarubicin, and G-CSF as induction chemotherapy for myelodysplasia-related acute myeloid leukemia2026
  5. 5Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025